- Today
- Holidays
- Birthdays
- Reminders
- Cities
- Atlanta
- Austin
- Baltimore
- Berwyn
- Beverly Hills
- Birmingham
- Boston
- Brooklyn
- Buffalo
- Charlotte
- Chicago
- Cincinnati
- Cleveland
- Columbus
- Dallas
- Denver
- Detroit
- Fort Worth
- Houston
- Indianapolis
- Knoxville
- Las Vegas
- Los Angeles
- Louisville
- Madison
- Memphis
- Miami
- Milwaukee
- Minneapolis
- Nashville
- New Orleans
- New York
- Omaha
- Orlando
- Philadelphia
- Phoenix
- Pittsburgh
- Portland
- Raleigh
- Richmond
- Rutherford
- Sacramento
- Salt Lake City
- San Antonio
- San Diego
- San Francisco
- San Jose
- Seattle
- Tampa
- Tucson
- Washington
South San Francisco Today
By the People, for the People
Twist Bioscience Stock Price Target Raised to $55 by Guggenheim
Analysts see 23% upside potential for the synthetic biology company's shares
Mar. 30, 2026 at 3:38pm
Got story updates? Submit your updates here. ›
Twist Bioscience's advanced DNA synthesis technology powers the company's growth in the synthetic biology market, as reflected in Guggenheim's increased price target.South San Francisco TodayGuggenheim analysts have increased their price target for Twist Bioscience (NASDAQ:TWST) stock from $50 to $55, representing a potential upside of 23% from the company's previous closing price. The investment firm maintained its 'buy' rating on the stock, citing the company's strong performance and growth prospects in the synthetic biology market.
Why it matters
Twist Bioscience is a leading player in the rapidly growing synthetic biology industry, which is expected to see significant growth in the coming years as demand for custom DNA and gene synthesis increases. The company's proprietary DNA synthesis platform has positioned it as a key supplier to various industries, including healthcare, agriculture, and industrial chemicals. The increased price target from Guggenheim reflects analysts' confidence in Twist's ability to capitalize on these market opportunities and drive shareholder value.
The details
Guggenheim's new $55 price target for Twist Bioscience represents a 23.13% increase from the company's previous closing price. The investment firm cited the company's strong financial performance and growth potential in the synthetic biology market as the primary reasons for the target price hike. Twist Bioscience has seen its stock price rise significantly in recent months, with the company's shares trading at around $44.67 on Monday.
- Guggenheim issued the new price target and 'buy' rating on Twist Bioscience on Monday, March 30, 2026.
The players
Twist Bioscience
A synthetic biology company that specializes in the development and commercialization of DNA-based products and solutions. The company has pioneered a proprietary silicon-based DNA synthesis platform designed for high-throughput production of synthetic genes and oligonucleotides.
Guggenheim
A global investment and advisory firm that provides financial services to institutional investors, corporations, and high-net-worth individuals. Guggenheim has issued a 'buy' rating and increased its price target for Twist Bioscience's stock.
What’s next
Investors will be closely watching Twist Bioscience's financial performance and growth in the synthetic biology market to see if the company can justify Guggenheim's increased price target and 'buy' rating.
The takeaway
Twist Bioscience's strong position in the rapidly growing synthetic biology industry has caught the attention of Wall Street analysts, with Guggenheim's increased price target and 'buy' rating reflecting their confidence in the company's ability to capitalize on market opportunities and drive shareholder value.
